Iowa Medicaid Drug Utilization Review (DUR) Commission Meeting March 4, 2009
|
|
- Silas Mitchell
- 5 years ago
- Views:
Transcription
1 CHESTER J. CULVER, GOVERNOR PATTY JUDGE, LT. GOVERNOR DEPARTMENT OF HUMAN SERVICES EUGENE I. GESSOW, DIRECTOR Iowa Medicaid Drug Utilization Review (DUR) Commission Meeting March 4, 2009 Location: Learning Resource Center 3550 Mills Civic Parkway West Des Moines, Iowa Time: 9:30 a.m. 1:30 p.m. Final Agenda 1. Welcome & Introductions a) Commission Members and Staff b) Approval of the minutes c) Old business 2. Iowa Medicaid Enterprise Update(s) a) February 20 th Clinical Advisory Committee Report b) Other IME/DHS Updates 3. P&T Committee s Recommendations on Select Mental Health Drugs Report from February 13 th Mental Health Advisory Group meeting 4. Prior Authorization a) Extended Release Formulations Prior Authorization Criteria b) Modified Formulations Prior Authorization Criteria 5. Public Comment (See Conflict of Interest Disclosure Form) 6. ProDUR Edits: Quantity Limits List: acetaminophen-containing analgesics 7. Focus Studies/Provider Education Initiatives a) New Clozapine Users and Frequency of Monitoring Follow up b) Concurrent Inhaled Anticholinergics Initial Review c) Protease Inhibitors with HMG CoA Inhibitors Initial Review d) Thiazolidinediones in Congestive Heart Failure Initial Review e) Use of Metered Dose Inhalers vs. Nebulizers Initial Review 8. Public Comment IOWA MEDICAID ENTERPRISE ARMY POST ROAD - DES MOINES, IA 50315
2 9. Miscellaneous a) DUR Digest (Draft) 2009 Volume 21, Number 2 b) MedWatch 10. Executive Closed Session a) Approval of Minutes b) Review of Focus Studies Data with PHI c) Member Profiles 11. Adjournment Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted twice during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to 5 minutes or less. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on. For more information contact the DUR Director, Chad Bissell, Pharm.D. at info@iadur.org or (515)
3 Attachment 1 Summary of Non-Preferred Recommendations from November 13, 2008 P & T Committee Meeting Summary of P&T Recommendations 1. Nonpreferred: Pexeva, Metadate CD, Ritalin LA. 2. Nonpreferred with Conditions 1 : Seroquel XR, Luvox CR, Risperdal M-Tab, Zyprexa Zydis, Abilify Discmelt, Pristiq, and Invega 3. Prior Authorization (PA) requirements recommended for those drugs in Nonpreferred with Conditions mean that the member must have a trial and failure of the parent compound. Classification of Recommendations I. Drugs A. Brand Name Products 1) Pexeva Non-Preferred 2) Metadate CD Non-Preferred 3) Ritalin LA Non-Preferred B. Extended Release Products* 1) Luvox CR Non-Preferred 2) Seroquel XR Non-Preferred C. Different Dosage Forms of Preferred Products* 1) Risperdal M-Tab Non-Preferred 2) Zyprexa Zydis Non-Preferred 3) Abilify Discmelt Non-Preferred D. Metabolites of Preferred Products* 1) Invega Non-Preferred 2) Pristiq Non-Preferred *With Conditions II. Prior Authorization Requirements Recommended Nonpreferred with Conditions mean that the member must have a trial and failure of the parent compound. 1 Conditions refers to the clinical prior authorization criteria developed and recommended by the DUR Commission that require specific medical criteria and guidelines be met as a condition for prior authorization approval.
4
5
6
7
8
9 Extended Release Formulations Existing PA Criteria Payment for the extended release formulation will be considered only for cases in which there is documentation of previous trial and therapy failure with the immediate release product of the same chemical entity, unless evidence is provided that use of the immediate release product would be medically contraindicated. Prior authorization is required for the following extended release formulation(s): 1) Luvox CR 2) Seroquel XR Proposed PA Criteria Payment for a non-preferred extended release formulation will be considered only for cases in which there is documentation of a previous trial and therapy failure with the immediate release product of the same chemical entity, unless evidence is provided that use of the immediate release product would be medically contraindicated. Drugs to be affected: Adoxa, Amrix, Allegra D 24 hr, Brovex CT, Cardura XL, Cipro XR, Coreg CR, diclofenac ER, Doryx, etodolac ER/CR, Extendryl SR, Flagyl ER, glipizide ER, Glucotrol XL, indomethacin ER, InnoPran XL, Luvox CR, Metadate CD, Opana ER, Prozac Weekly, Quibron-T/SR, Requip XL, Ritalin LA, Seroquel XR, Sinemet CR, Solodyn ER, Ultram ER, Xanax XR*. *Currently included on the Benzodiazepine Prior Authorization form
10 Modified Formulations At the November 13 th P&T Committee Meeting, the members of the P&T Committee requested the DUR Commission develop clinical prior authorization criteria for the medications currently on the Recommended Drug List which will be moving to the Preferred Drug List. These medications are modified formulations of existing products. This was originally discussed at the May 2008 DUR Meeting. Proposed PA Criteria Payment for an isomer, pro-drug, metabolite, and/or alternative delivery system will only be considered for cases in which there is documentation of a recent trial and therapy failure with the original parent drug product of the same chemical entity, unless evidence is provided that use of the original product would be medically contraindicated. Prior Authorization is required for the following modified formulations: 1) Invega 4) Zyprexa Zydis 2) Pristiq 5) Abilify Discmelt 3) Risperdal-M Tabs
11 Iowa DUR Claims Outside of Monthly Quantity Limits on Acetaminophen-Containing Analgesics for the Period of 07/01/2008 to 11/30/2008 *Suggested quantity limits are based on the maximum daily dose of acetaminophen (4000mg per 24 hours). Drug Description Qty Limit* Member Count Claim Count Paid Amt Acetaminophen Tab 500 MG $ Hydrocodone-Acetaminophen Tab MG $ Hydrocodone-Acetaminophen Tab MG $ Hydrocodone-Acetaminophen Tab MG $37.50 Oxycodone w/ Acetaminophen Tab MG $47.37 Propoxyphene-N w/ APAP Tab MG $1, $2, RT
12 Iowa DUR Claims Outside of Daily Quantity Limits on Acetaminophen-Containing Analgesics for the Period of 07/01/2008 to 11/30/2008 *Suggested quantity limits are based on the maximum daily dose of acetaminophen (4000mg per 24 hours). Daily Qty Drug Description Limit Member Count Claim Count Paid Amt Pentazocine w/ APAP Tab MG $53.80 Hydrocodone-Acetaminophen Tab MG $81.48 Hydrocodone-Acetaminophen Tab MG $ Tramadol-Acetaminophen Tab MG $ Oxycodone w/ Acetaminophen Tab MG $1, Oxycodone w/ Acetaminophen Tab MG $ Oxycodone w/ Acetaminophen Tab MG $ Acetaminophen w/ Codeine Tab MG $47.84 Hydrocodone-Acetaminophen Tab MG 8 3,817 5,283 $29, Hydrocodone-Acetaminophen Tab MG $ Propoxyphene-N w/ APAP Tab MG $56.22 Propoxyphene-N w/ APAP Tab MG 6 1,526 2,196 $23, Butalbital-Acetaminophen-Caffeine Tab $ MG Acetaminophen Tab 500 MG $1, Hydrocodone-Acetaminophen Tab MG $42.16 Butalbital-Acetaminophen-Caff w/ COD Cap $ MG Hydrocodone-Acetaminophen Tab MG $6, Hydrocodone-Acetaminophen Tab MG $1, Oxycodone w/ Acetaminophen Tab MG $96.41 Butalbital-Acetaminophen Tab MG $11.62 Acetaminophen w/ Codeine Tab MG $4, Butalbital-Acetaminophen-Caffeine Tab $ MG Acetaminophen w/ Codeine Soln MG/5ML $ RT
13 Daily Qty Drug Description Limit Member Count Claim Count Paid Amt Hydrocodone-Acetaminophen Tab MG $4, Hydrocodone-Acetaminophen Tab MG $2, Oxycodone w/ Acetaminophen Cap MG $ Oxycodone w/ Acetaminophen Tab MG $7, Acetaminophen w/ Codeine Tab MG $6.57 Hydrocodone-Acetaminophen Tab MG $3, Hydrocodone-Acetaminophen Soln $4, MG/15ML Hydrocodone-Acetaminophen Tab MG $ Hydrocodone-Acetaminophen Tab MG $ Oxycodone w/ Acetaminophen Tab MG $ ,333 11,348 $96, RT
14 Iowa DUR Select Members with Utilization in Narcotics - Misc, Narcotics - Selected, Analgesics - Misc and/or NSAIDS PDL Categories for the Period of 08/01/2008 to 11/30/2008 Purpose: To look at those members identified as exceeding the proposed quantity limits for the short acting narcotics, who may also be taking one or more drugs from the following PDL categories: narcotics - misc, narcotics - selected, analgesics - misc, and/or NSAIDS. RX Num DOS Qty Days Supply Drug Description RX Num DOS Qty Days Supply Drug Description Member: Z /15/ /15/ /10/ /10/ Member: Z /01/ IBUPROFEN TAB 600MG /15/ /01/ IBUPROFEN TAB 600MG /16/ /06/ /25/ /03/ IBUPROFEN TAB 600MG Member: Z /19/ /16/ /20/ /11/ HYDROCO/APAP TAB 5-500MG /17/ Member: Z /30/ /25/ Member: Z /06/ /26/ /23/ /26/ SULINDAC TAB 200MG /24/ /20/ DICLOFENAC TAB 75MG DR Member: Z /18/ HYDROCO/APAP TAB /12/ HYDROCO/APAP TAB /03/ SULINDAC TAB 200MG /09/ HYDROCO/APAP TAB /05/ HYDROCO/APAP TAB /05/ TRAMADOL HCL TAB 50MG /28/ TRAMADOL HCL TAB 50MG Member: Z /12/ TRAMADOL HCL TAB 50MG /19/ /13/ /12/ HYDROCO/APAP TAB 5-500MG /14/ /11/ RT
15 RX Num DOS Qty Days Supply Drug Description RX Num DOS Qty Days Supply Drug Description Member: Z /08/ HYDROCO/APAP TAB 5-500MG /05/ OXYCOD/APAP TAB 5-325MG /30/ OXYCOD/APAP TAB 5-325MG /28/ OXYCOD/APAP TAB 5-325MG /26/ OXYCOD/APAP TAB 5-325MG Member: Z /30/ /05/ OXYCOD/APAP TAB 5-325MG /17/ Member: Z /01/ GENEBS TAB 325MG /01/ ASPIRIN TAB 325MG /01/ TRAMADOL HCL TAB 50MG /07/ APAP/CODEINE TAB MG /12/ TRAMADOL HCL TAB 50MG /13/ VOLTAREN GEL 1% /01/ ASPIRIN TAB 325MG /01/ TRAMADOL HCL TAB 50MG /02/ ASPIRIN TAB 325MG EC /02/ TRAMADOL HCL TAB 50MG /11/ HYDROCO/APAP TAB 5-500MG /02/ HYDROCO/APAP TAB 5-500MG /02/ TRAMADOL HCL TAB 50MG /10/ IBUPROFEN TAB 600MG /04/ HYDROCO/APAP TAB 5-500MG /04/ IBUPROFEN TAB 600MG /04/ TRAMADOL HCL TAB 50MG Member: Z /15/ HYDROCO/APAP TAB MG /20/ HYDROCO/APAP TAB MG Member: Z /21/ INDOMETHACIN CAP 50MG /21/ /17/ /17/ ASPIRIN TAB 81MG EC /11/ INDOMETHACIN CAP 50MG /13/ /16/ ASA LOW DOSE TAB 81MG EC /10/ INDOMETHACIN CAP 50MG /10/ ASA LOW DOSE TAB 81MG EC /10/ Member: Z /16/ Member: Z /26/ HYDROCO/APAP TAB /03/ HYDROCO/APAP TAB /06/ HYDROCO/APAP TAB /17/ HYDROCO/APAP TAB Member: Z /18/ OXYCOD/APAP TAB 5-325MG /17/ OXYCOD/APAP TAB 5-325MG /16/ OXYCOD/APAP TAB 5-325MG /29/ OXYCOD/APAP TAB 5-325MG /17/ OXYCOD/APAP TAB 5-325MG Member: Z RT
16 Distinct Clients 16 RT
17 IOWA DUR Clozapine/Fazaclo Study for the Period of 5/1/2008 to 12/31/2008 Purpose: To identify new starters of clozapine and follow monitoring for White Blood Count (WBC), Absolute Neutrophil Count (ANC), and clozapine blood levels. A secondary purpose was to determine the effect, if any, of clozapine use on doses of atypical antipsychotics. Note: Drugs and Procedures are shown in the same column. Procedures are highlighted. DOS RX_Num/ Quantity Days Supply Product/Procedure Description Proc Code Z 12/15/ CLOZAPINE TAB 100MG 12/15/ CLOZAPINE TAB 25MG 11/18/ CLOZAPINE TAB 25MG 11/10/ CLOZAPINE TAB 100MG 10/20/ CLOZAPINE TAB 100MG 10/20/ CLOZAPINE TAB 25MG 09/22/ CLOZAPINE TAB 25MG 09/22/ CLOZAPINE TAB 100MG 08/28/ CLOZAPINE TAB 100MG 08/28/ CLOZAPINE TAB 25MG 07/28/ CLOZAPINE TAB 25MG 07/28/ CLOZAPINE TAB 100MG 07/07/ CLOZAPINE TAB 100MG 07/07/ CLOZAPINE TAB 25MG Z 12/14/ FAZACLO TAB 100MG 12/14/ SEROQUEL TAB 200MG 11/14/ FAZACLO TAB 100MG 11/14/ SEROQUEL TAB 200MG 11/11/ SEROQUEL TAB 200MG 11/11/ FAZACLO TAB 100MG 10/15/ FAZACLO TAB 100MG 10/14/ SEROQUEL TAB 300MG 10/08/ FAZACLO TAB 100MG 09/14/ SEROQUEL TAB 300MG 09/14/ CLOZAPINE TAB 100MG 08/20/ CLOZAPINE TAB 100MG 08/14/ SEROQUEL TAB 300MG 08/14/ CLOZAPINE TAB 100MG 07/17/ CLOZAPINE TAB 100MG 07/14/ SEROQUEL TAB 300MG 07/11/ SEROQUEL TAB 300MG 06/14/ SEROQUEL TAB 200MG 05/14/ SEROQUEL TAB 200MG RT
18 DOS RX_Num/ Quantity Days Supply Product/Procedure Description Proc Code Z 12/26/ CLOZAPINE TAB 100MG 12/17/ CLOZAPINE TAB 100MG 12/15/ /12/ CLOZAPINE TAB 100MG 12/05/ CLOZAPINE TAB 100MG 11/28/ CLOZAPINE TAB 100MG 11/21/ CLOZAPINE TAB 100MG 11/14/ CLOZAPINE TAB 100MG 11/07/ CLOZAPINE TAB 100MG 10/31/ CLOZAPINE TAB 100MG 10/25/ CLOZAPINE TAB 100MG 10/17/ CLOZAPINE TAB 100MG 10/10/ CLOZAPINE TAB 100MG 10/06/ /03/ CLOZAPINE TAB 100MG 09/26/ CLOZAPINE TAB 100MG 09/19/ CLOZAPINE TAB 100MG 09/13/ CLOZAPINE TAB 100MG 09/05/ CLOZAPINE TAB 100MG 08/29/ CLOZAPINE TAB 100MG 08/22/ CLOZAPINE TAB 100MG 08/15/ CLOZAPINE TAB 100MG 08/08/ CLOZAPINE TAB 100MG 07/30/ CLOZAPINE TAB 100MG 07/22/ CLOZAPINE TAB 100MG 07/17/ CLOZAPINE TAB 100MG 07/09/ CLOZAPINE TAB 100MG 07/02/ CLOZAPINE TAB 100MG 07/01/ CLOZAPINE TAB 25MG 06/27/ CLOZAPINE TAB 25MG 06/20/ CLOZAPINE TAB 25MG 06/13/ CLOZAPINE TAB 25MG 06/06/ CLOZAPINE TAB 25MG 05/30/ CLOZAPINE TAB 25MG 05/16/ RISPERDAL TAB 2MG RT
19 DOS RX_Num/ Quantity Days Supply Product/Procedure Description Proc Code Z 12/22/ RISPERDAL INJ 50MG 12/11/ CLOZAPINE TAB 25MG 12/11/ INVEGA TAB 6MG 12/08/ RISPERDAL INJ 50MG 11/22/ RISPERDAL INJ 50MG 11/14/ CLOZAPINE TAB 25MG 11/14/ RISPERDAL TAB 4MG 11/14/ INVEGA TAB 6MG 11/11/ RISPERDAL INJ 50MG 10/27/ RISPERDAL INJ 50MG 10/17/ CLOZAPINE TAB 25MG 10/16/ RISPERDAL TAB 4MG 10/13/ RISPERDAL INJ 50MG 09/26/ RISPERDAL INJ 50MG 09/22/ RISPERDAL TAB 4MG 09/22/ CLOZAPINE TAB 25MG 09/15/ RISPERDAL INJ 50MG 09/03/ RISPERDAL INJ 50MG 08/21/ RISPERDAL TAB 4MG 08/21/ CLOZAPINE TAB 25MG 08/20/ RISPERDAL INJ 50MG 08/01/ RISPERDAL INJ 50MG 07/23/ RISPERIDONE TAB 4MG 07/22/ RISPERDAL INJ 50MG 07/22/ CLOZAPINE TAB 25MG 07/09/ RISPERDAL INJ 50MG 06/26/ RISPERDAL INJ 50MG 06/25/ RISPERDAL TAB 4MG 06/25/ CLOZAPINE TAB 25MG 06/04/ RISPERDAL TAB 4MG 06/04/ RISPERDAL INJ 50MG 05/08/ RISPERDAL TAB 4MG 05/01/ RISPERDAL INJ 50MG RT
20 DOS RX_Num/ Quantity Days Supply Product/Procedure Description Proc Code Z 12/19/ CLOZAPINE TAB 100MG 12/19/ CLOZAPINE TAB 25MG 12/18/ /25/ CLOZAPINE TAB 100MG 11/25/ CLOZAPINE TAB 25MG 11/21/ /29/ CLOZAPINE TAB 25MG 10/29/ CLOZAPINE TAB 100MG 10/28/ /27/ /01/ CLOZAPINE TAB 25MG 10/01/ CLOZAPINE TAB 100MG 09/29/ /03/ CLOZAPINE TAB 100MG 09/03/ CLOZAPINE TAB 25MG 09/02/ /04/ CLOZAPINE TAB 25MG 08/04/ CLOZAPINE TAB 100MG 08/01/ /22/ CLOZAPINE TAB 25MG 07/22/ CLOZAPINE TAB 100MG 07/09/ CLOZAPINE TAB 25MG 07/09/ CLOZAPINE TAB 100MG 07/07/ /25/ CLOZAPINE TAB 25MG 06/25/ CLOZAPINE TAB 100MG 06/24/ Z 12/27/ /20/ /13/ /06/ /29/ /22/ /15/ /08/ /01/ /25/ /20/ /11/ /04/ /27/ /20/ /13/ /06/ /30/ /25/ /16/ /09/ /02/ /26/ /19/ /12/ /05/ /02/ RT
21 DOS RX_Num/ Quantity Days Supply Product/Procedure Description Proc Code Z 12/17/ CLOZAPINE TAB 25MG 12/16/ /23/ CLOZAPINE TAB 25MG 11/07/ CLOZAPINE TAB 25MG 10/31/ CLOZAPINE TAB 25MG 10/24/ CLOZAPINE TAB 25MG 10/17/ CLOZAPINE TAB 25MG 10/17/ /10/ CLOZAPINE TAB 25MG 10/03/ CLOZAPINE TAB 25MG 10/02/ /09/ ABILIFY TAB 30MG 06/25/ ABILIFY TAB 30MG 06/06/ ABILIFY TAB 30MG 05/30/ ABILIFY TAB 30MG Z 12/08/ CLOZAPINE TAB 100MG 12/08/ CLOZAPINE TAB 100MG 12/08/ CLOZAPINE TAB 200MG 11/22/ CLOZAPINE TAB 25MG 11/22/ CLOZAPINE TAB 100MG 11/07/ CLOZAPINE TAB 100MG 11/07/ CLOZAPINE TAB 25MG 10/24/ CLOZAPINE TAB 25MG 10/24/ CLOZAPINE TAB 100MG 10/13/ CLOZAPINE TAB 100MG 10/13/ CLOZAPINE TAB 25MG 09/30/ CLOZAPINE TAB 100MG 09/30/ CLOZAPINE TAB 25MG 09/16/ CLOZAPINE TAB 25MG 09/16/ CLOZAPINE TAB 100MG 08/28/ CLOZAPINE TAB 100MG 08/28/ CLOZAPINE TAB 25MG 08/15/ CLOZAPINE TAB 100MG 08/15/ CLOZAPINE TAB 25MG 08/01/ CLOZAPINE TAB 25MG 08/01/ CLOZAPINE TAB 100MG 07/21/ CLOZAPINE TAB 100MG 07/21/ CLOZAPINE TAB 25MG 07/08/ CLOZAPINE TAB 25MG 07/08/ CLOZAPINE TAB 100MG 06/24/ CLOZAPINE TAB 100MG 06/24/ CLOZAPINE TAB 25MG 06/09/ CLOZAPINE TAB 25MG 06/09/ CLOZAPINE TAB 100MG 05/27/ CLOZAPINE TAB 25MG 05/27/ CLOZAPINE TAB 100MG RT
22 DOS RX_Num/ Quantity Days Supply Product/Procedure Description Proc Code Z 12/24/ FAZACLO TAB 100MG 12/24/ FAZACLO TAB 25MG 12/09/ FAZACLO TAB 100MG 11/24/ FAZACLO TAB 100MG 11/12/ FAZACLO TAB 100MG 10/28/ FAZACLO TAB 100MG 10/14/ FAZACLO TAB 100MG 09/30/ FAZACLO TAB 100MG 09/16/ FAZACLO TAB 100MG 09/05/ FAZACLO TAB 100MG 08/19/ FAZACLO TAB 100MG 08/18/ FAZACLO TAB 100MG 08/12/ FAZACLO TAB 25MG 07/08/ SEROQUEL XR TAB 400MG 06/20/ SEROQUEL XR TAB 300MG 05/16/ SEROQUEL XR TAB 300MG Z 12/20/ CLOZAPINE TAB 25MG 12/07/ CLOZAPINE TAB 25MG 12/05/ /05/ LEUKOCYTE (WBC) AUTOMATE 11/23/ CLOZAPINE TAB 25MG 11/21/ /21/ LEUKOCYTE (WBC) AUTOMATE 11/07/ LEUKOCYTE (WBC) AUTOMATE 11/07/ /07/ CLOZAPINE TAB 25MG 10/24/ /24/ LEUKOCYTE (WBC) AUTOMATE 10/23/ CLOZAPINE TAB 25MG 10/12/ CLOZAPINE TAB 25MG 10/10/ LEUKOCYTE (WBC) AUTOMATE 10/10/ /25/ /25/ LEUKOCYTE (WBC) AUTOMATE 09/25/ CLOZAPINE TAB 25MG 09/12/ CLOZAPINE TAB 25MG 09/12/ /31/ CLOZAPINE TAB 25MG 08/28/ /28/ LEUKOCYTE (WBC) AUTOMATE 08/17/ CLOZAPINE TAB 25MG 08/15/ /15/ LEUKOCYTE (WBC) AUTOMATE RT
23 DOS RX_Num/ Quantity Days Supply Product/Procedure Description Proc Code Z 10/10/ ZYPREXA TAB 10MG 09/06/ CLOZAPINE TAB 100MG 09/03/ ZYPREXA ZYDI TAB 10MG 08/30/ CLOZAPINE TAB 25MG 07/25/ /10/ CLOZAPINE TAB 25MG 07/10/ CLOZAPINE TAB 100MG 07/04/ CLOZAPINE TAB 100MG 06/28/ CLOZAPINE TAB 100MG 06/23/ CLOZAPINE TAB 100MG 06/18/ /16/ CLOZAPINE TAB 100MG 06/13/ CLOZAPINE TAB 25MG 06/07/ CLOZAPINE TAB 25MG 06/02/ CLOZAPINE TAB 25MG Z 12/17/ CLOZAPINE TAB 100MG 11/24/ CLOZAPINE TAB 100MG 11/06/ CLOZAPINE TAB 100MG 10/27/ CLOZAPINE TAB 100MG 10/10/ CLOZAPINE TAB 100MG 09/26/ CLOZAPINE TAB 100MG 09/05/ CLOZAPINE TAB 100MG 08/15/ CLOZAPINE TAB 100MG 07/28/ CLOZAPINE TAB 100MG 07/16/ CLOZAPINE TAB 100MG 07/01/ CLOZAPINE TAB 100MG RT
24 DOS RX_Num/ Quantity Days Supply Product/Procedure Description Proc Code Z 12/23/ ABILIFY TAB 15MG 12/23/ ABILIFY TAB 10MG 12/23/ CLOZAPINE TAB 100MG 12/11/ ABILIFY TAB 20MG 11/24/ CLOZAPINE TAB 100MG 11/19/ /13/ /10/ ZYPREXA TAB 10MG 11/07/ /31/ /23/ /16/ /11/ ZYPREXA TAB 10MG 10/10/ /03/ /26/ /20/ /11/ /11/ ZYPREXA TAB 10MG 09/06/ /29/ /12/ ZYPREXA TAB 10MG 07/31/ CLOZAPINE TAB 100MG 07/30/ ZYPREXA TAB 20MG 06/20/ ZYPREXA TAB 20MG 06/20/ SEROQUEL TAB 400MG 05/23/ SEROQUEL TAB 400MG 05/23/ ZYPREXA TAB 20MG 05/12/ SEROQUEL TAB 400MG 05/12/ ZYPREXA TAB 20MG RT
25 DOS RX_Num/ Quantity Days Supply Product/Procedure Description Proc Code Z 12/31/ CLOZAPINE TAB 100MG 12/12/ CLOZAPINE TAB 200MG 12/12/ CLOZAPINE TAB 25MG 12/12/ CLOZAPINE TAB 50MG 12/11/ CLOZAPINE TAB 100MG 12/01/ CLOZAPINE TAB 50MG 12/01/ CLOZAPINE TAB 200MG 12/01/ CLOZAPINE TAB 25MG 11/26/ CLOZAPINE TAB 200MG 11/26/ CLOZAPINE TAB 25MG 11/26/ CLOZAPINE TAB 50MG 11/01/ CLOZAPINE TAB 50MG 11/01/ CLOZAPINE TAB 25MG 11/01/ CLOZAPINE TAB 200MG 10/20/ CLOZAPINE TAB 25MG 10/20/ CLOZAPINE TAB 50MG 10/01/ CLOZAPINE TAB 200MG 10/01/ CLOZAPINE TAB 50MG 09/02/ CLOZAPINE TAB 200MG 09/02/ CLOZAPINE TAB 50MG 08/22/ CLOZAPINE TAB 50MG 08/22/ CLOZAPINE TAB 200MG 08/01/ CLOZAPINE TAB 100MG 07/17/ CLOZAPINE TAB 50MG 07/17/ CLOZAPINE TAB 100MG 07/17/ CLOZAPINE TAB 100MG 07/07/ CLOZAPINE TAB 100MG 07/01/ CLOZAPINE TAB 25MG 07/01/ CLOZAPINE TAB 100MG 06/17/ CLOZAPINE TAB 100MG 06/02/ CLOZAPINE TAB 50MG 06/02/ ABILIFY TAB 10MG 06/02/ CLOZAPINE TAB 25MG 06/01/ GEODON CAP 80MG 06/01/ ABILIFY TAB 20MG 05/01/ GEODON CAP 80MG 05/01/ GEODON CAP 40MG 05/01/ ABILIFY TAB 20MG Z 12/30/ CLOZAPINE TAB 25MG 11/28/ CLOZAPINE TAB 25MG 10/27/ CLOZAPINE TAB 100MG 09/20/ CLOZAPINE TAB 100MG 08/21/ CLOZAPINE TAB 100MG 07/22/ CLOZAPINE TAB 100MG 06/26/ CLOZAPINE TAB 100MG 06/12/ CLOZAPINE TAB 25MG 06/11/ SEROQUEL TAB 100MG Z 12/01/ CLOZAPINE TAB 100MG 11/03/ CLOZAPINE TAB 100MG 10/01/ CLOZAPINE TAB 100MG 09/03/ CLOZAPINE TAB 100MG 08/01/ CLOZAPINE TAB 100MG 07/02/ CLOZAPINE TAB 100MG 06/26/ CLOZAPINE TAB 100MG RT
26 DOS RX_Num/ Quantity Days Supply Product/Procedure Description Proc Code Z 12/22/ CLOZAPINE TAB 100MG 12/08/ CLOZAPINE TAB 100MG 11/25/ CLOZAPINE TAB 100MG 11/11/ CLOZAPINE TAB 200MG 11/11/ CLOZAPINE TAB 50MG 11/01/ CLOZAPINE TAB 200MG 11/01/ CLOZAPINE TAB 50MG 10/01/ CLOZAPINE TAB 50MG 10/01/ CLOZAPINE TAB 200MG 09/01/ CLOZAPINE TAB 200MG 09/01/ CLOZAPINE TAB 50MG 08/01/ CLOZAPINE TAB 50MG 08/01/ CLOZAPINE TAB 200MG 07/12/ CLOZAPINE TAB 50MG 07/09/ CLOZAPINE TAB 25MG 07/09/ CLOZAPINE TAB 200MG 07/01/ CLOZAPINE TAB 100MG 07/01/ CLOZAPINE TAB 50MG 07/01/ CLOZAPINE TAB 200MG 06/25/ CLOZAPINE TAB 100MG 06/01/ CLOZAPINE TAB 50MG 06/01/ CLOZAPINE TAB 200MG 05/28/ CLOZAPINE TAB 100MG 05/28/ CLOZAPINE TAB 50MG 05/28/ CLOZAPINE TAB 200MG 05/23/ CLOZAPINE TAB 25MG 05/23/ CLOZAPINE TAB 100MG RT
27 DOS RX_Num/ Quantity Days Supply Product/Procedure Description Proc Code Z 12/29/ CLOZAPINE TAB 100MG 12/29/ CLOZAPINE TAB 50MG 12/24/ CLOZAPINE TAB 100MG 12/24/ CLOZAPINE TAB 50MG 12/24/ GEODON CAP 40MG 12/20/ CLOZAPINE TAB 100MG 12/20/ CLOZAPINE TAB 50MG 12/20/ GEODON CAP 40MG 12/06/ CLOZAPINE TAB 100MG 12/06/ CLOZAPINE TAB 50MG 12/06/ GEODON CAP 40MG 11/30/ GEODON CAP 40MG 11/30/ CLOZAPINE TAB 100MG 11/30/ CLOZAPINE TAB 50MG 11/27/ CLOZAPINE TAB 100MG 11/27/ CLOZAPINE TAB 50MG 11/27/ GEODON CAP 40MG 11/26/ CLOZAPINE TAB 100MG 11/26/ CLOZAPINE TAB 50MG 11/26/ GEODON CAP 40MG 11/22/ CLOZAPINE TAB 100MG 11/22/ CLOZAPINE TAB 50MG 11/22/ GEODON CAP 40MG 11/01/ CLOZAPINE TAB 100MG 11/01/ GEODON CAP 40MG 11/01/ CLOZAPINE TAB 50MG 10/01/ CLOZAPINE TAB 50MG 10/01/ GEODON CAP 40MG 10/01/ CLOZAPINE TAB 100MG 09/30/ CLOZAPINE TAB 50MG 09/12/ CLOZAPINE TAB 25MG 09/12/ CLOZAPINE TAB 100MG 09/04/ GEODON CAP 40MG 09/02/ GEODON CAP 40MG 09/02/ CLOZAPINE TAB 100MG 09/02/ CLOZAPINE TAB 25MG 08/19/ CLOZAPINE TAB 25MG 08/19/ CLOZAPINE TAB 50MG 08/13/ GEODON CAP 40MG 08/06/ GEODON CAP 20MG 08/06/ GEODON CAP 60MG 08/01/ GEODON CAP 40MG 07/16/ ABILIFY TAB 10MG 07/16/ GEODON CAP 20MG 07/16/ GEODON CAP 40MG 07/16/ GEODON CAP 40MG 07/02/ GEODON CAP 40MG 07/01/ ABILIFY TAB 20MG 07/01/ ABILIFY TAB 5MG 06/01/ ABILIFY TAB 20MG 06/01/ ABILIFY TAB 5MG 05/01/ ABILIFY TAB 20MG 05/01/ ABILIFY TAB 5MG RT
28 DOS RX_Num/ Quantity Days Supply Product/Procedure Description Proc Code Z 12/24/ CLOZAPINE TAB 200MG 12/24/ CLOZAPINE TAB 50MG 12/14/ CLOZAPINE TAB 200MG 12/14/ CLOZAPINE TAB 50MG 12/01/ CLOZAPINE TAB 50MG 12/01/ CLOZAPINE TAB 200MG 11/27/ CLOZAPINE TAB 200MG 11/27/ CLOZAPINE TAB 50MG 11/01/ CLOZAPINE TAB 200MG 11/01/ CLOZAPINE TAB 50MG 10/06/ CLOZAPINE TAB 50MG 10/01/ CLOZAPINE TAB 200MG 09/01/ CLOZAPINE TAB 200MG 08/20/ CLOZAPINE TAB 25MG 08/20/ CLOZAPINE TAB 200MG 08/07/ CLOZAPINE TAB 25MG 08/07/ CLOZAPINE TAB 50MG 08/01/ CLOZAPINE TAB 100MG 07/28/ CLOZAPINE TAB 25MG 07/28/ CLOZAPINE TAB 100MG 07/09/ CLOZAPINE TAB 100MG 07/08/ CLOZAPINE TAB 100MG 07/08/ CLOZAPINE TAB 25MG 07/03/ CLOZAPINE TAB 25MG 07/03/ CLOZAPINE TAB 100MG 06/25/ CLOZAPINE TAB 100MG 06/25/ CLOZAPINE TAB 25MG 06/18/ CLOZAPINE TAB 25MG 06/18/ CLOZAPINE TAB 100MG 06/12/ CLOZAPINE TAB 25MG 06/12/ CLOZAPINE TAB 100MG 06/05/ CLOZAPINE TAB 100MG 06/05/ CLOZAPINE TAB 25MG 05/29/ CLOZAPINE TAB 100MG 05/29/ CLOZAPINE TAB 25MG 05/22/ CLOZAPINE TAB 100MG 05/22/ CLOZAPINE TAB 25MG Z 12/23/ CLOZAPINE TAB 50MG 12/23/ CLOZAPINE TAB 100MG 12/23/ CLOZAPINE TAB 50MG 12/17/ CLOZAPINE TAB 100MG 12/06/ CLOZAPINE TAB 50MG 12/03/ CLOZAPINE TAB 25MG 12/01/ CLOZAPINE TAB 100MG 11/26/ CLOZAPINE TAB 100MG 11/01/ CLOZAPINE TAB 100MG 10/01/ CLOZAPINE TAB 50MG 10/01/ CLOZAPINE TAB 100MG 10/01/ ABILIFY TAB 5MG 09/25/ CLOZAPINE TAB 50MG 09/25/ CLOZAPINE TAB 100MG 09/25/ ABILIFY TAB 5MG 09/08/ CLOZAPINE TAB 25MG 09/08/ ABILIFY TAB 10MG 09/08/ CLOZAPINE TAB 50MG 08/26/ ABILIFY TAB 15MG RT
29 DOS RX_Num/ Quantity Days Supply Product/Procedure Description Proc Code Z 12/31/ /29/ /24/ /18/ /10/ /10/ LEUKOCYTE (WBC) AUTOMATE 12/03/ /24/ LEUKOCYTE (WBC) AUTOMATE 11/22/ /21/ LEUKOCYTE (WBC) AUTOMATE 11/17/ /10/ /04/ /03/ LEUKOCYTE (WBC) AUTOMATE 10/30/ /29/ LEUKOCYTE (WBC) AUTOMATE 10/24/ /17/ /13/ LEUKOCYTE (WBC) AUTOMATE 10/10/ /06/ LEUKOCYTE (WBC) AUTOMATE 10/02/ /29/ LEUKOCYTE (WBC) AUTOMATE 09/25/ CLOZAPINE TAB 100MG 09/22/ LEUKOCYTE (WBC) AUTOMATE 09/15/ LEUKOCYTE (WBC) AUTOMATE 09/11/ CLOZAPINE TAB 25MG 09/11/ CLOZAPINE TAB 100MG 09/08/ LEUKOCYTE (WBC) AUTOMATE 08/28/ CLOZAPINE TAB 25MG 08/22/ LEUKOCYTE (WBC) AUTOMATE 08/07/ CLOZAPINE TAB 25MG 07/25/ CLOZAPINE TAB 25MG 07/24/ LEUKOCYTE (WBC) AUTOMATE RT
30 DOS RX_Num/ Quantity Days Supply Product/Procedure Description Proc Code Z 12/30/ CLOZAPINE TAB 200MG 12/30/ CLOZAPINE TAB 50MG 12/23/ CLOZAPINE TAB 200MG 12/23/ CLOZAPINE TAB 50MG 12/12/ CLOZAPINE TAB 200MG 12/12/ CLOZAPINE TAB 50MG 12/06/ CLOZAPINE TAB 200MG 12/05/ CLOZAPINE TAB 50MG 12/02/ CLOZAPINE TAB 50MG 12/02/ CLOZAPINE TAB 100MG 12/01/ CLOZAPINE TAB 50MG 12/01/ CLOZAPINE TAB 25MG 12/01/ CLOZAPINE TAB 100MG 11/26/ CLOZAPINE TAB 100MG 11/26/ CLOZAPINE TAB 25MG 11/26/ CLOZAPINE TAB 50MG 11/01/ CLOZAPINE TAB 100MG 11/01/ CLOZAPINE TAB 50MG 11/01/ CLOZAPINE TAB 25MG 10/14/ GEODON CAP 20MG 10/13/ CLOZAPINE TAB 50MG 10/10/ CLOZAPINE TAB 50MG 10/03/ CLOZAPINE TAB 100MG 10/01/ CLOZAPINE TAB 50MG 10/01/ CLOZAPINE TAB 25MG 10/01/ GEODON CAP 40MG 09/25/ CLOZAPINE TAB 25MG 09/25/ GEODON CAP 40MG 09/25/ CLOZAPINE TAB 50MG 09/01/ GEODON CAP 20MG 08/01/ GEODON CAP 20MG 07/01/ GEODON CAP 20MG RT
31 DOS RX_Num/ Quantity Days Supply Product/Procedure Description Proc Code Z 12/24/ CLOZAPINE TAB 200MG 12/20/ CLOZAPINE TAB 200MG 12/13/ CLOZAPINE TAB 200MG 12/06/ CLOZAPINE TAB 200MG 12/01/ CLOZAPINE TAB 50MG 11/30/ CLOZAPINE TAB 200MG 11/27/ CLOZAPINE TAB 200MG 11/27/ CLOZAPINE TAB 50MG 11/22/ CLOZAPINE TAB 200MG 11/22/ CLOZAPINE TAB 50MG 11/14/ CLOZAPINE TAB 50MG 11/01/ CLOZAPINE TAB 50MG 11/01/ CLOZAPINE TAB 200MG 10/25/ CLOZAPINE TAB 50MG 10/22/ CLOZAPINE TAB 25MG 10/07/ GEODON CAP 40MG 10/01/ GEODON CAP 80MG 10/01/ CLOZAPINE TAB 200MG 10/01/ GEODON CAP 40MG 09/01/ GEODON CAP 80MG 09/01/ GEODON CAP 40MG 09/01/ CLOZAPINE TAB 200MG 08/01/ GEODON CAP 40MG 08/01/ GEODON CAP 80MG 08/01/ CLOZAPINE TAB 200MG 07/24/ CLOZAPINE TAB 200MG 07/05/ CLOZAPINE TAB 50MG 07/01/ CLOZAPINE TAB 100MG 07/01/ GEODON CAP 80MG 07/01/ GEODON CAP 40MG 06/30/ CLOZAPINE TAB 100MG 06/27/ CLOZAPINE TAB 25MG 06/27/ CLOZAPINE TAB 50MG 06/03/ GEODON CAP 40MG 06/03/ GEODON CAP 80MG 06/02/ GEODON CAP 20MG 06/02/ CLOZAPINE TAB 50MG 06/02/ CLOZAPINE TAB 100MG 06/01/ CLOZAPINE TAB 200MG 06/01/ GEODON CAP 40MG 06/01/ CLOZAPINE TAB 100MG 06/01/ CLOZAPINE TAB 25MG 05/27/ CLOZAPINE TAB 200MG 05/27/ CLOZAPINE TAB 25MG 05/27/ CLOZAPINE TAB 100MG 05/22/ CLOZAPINE TAB 50MG 05/22/ CLOZAPINE TAB 25MG 05/22/ CLOZAPINE TAB 100MG 05/22/ RISPERDAL TAB 0.5MG 05/13/ RISPERDAL TAB 1MG 05/13/ CLOZAPINE TAB 25MG 05/13/ GEODON CAP 40MG 05/01/ RISPERDAL TAB 2MG 05/01/ RISPERDAL TAB 0.5MG 05/01/ GEODON CAP 40MG 05/01/ GEODON CAP 80MG RT
32 DOS RX_Num/ Quantity Days Supply Product/Procedure Description Proc Code Z 12/19/ CLOZAPINE TAB 100MG 11/24/ CLOZAPINE TAB 100MG 10/27/ CLOZAPINE TAB 100MG 09/26/ CLOZAPINE TAB 100MG 09/24/ CLOZAPINE TAB 100MG 08/27/ CLOZAPINE TAB 100MG 07/29/ CLOZAPINE TAB 100MG 07/28/ CLOZAPINE TAB 100MG 06/13/ CLOZAPINE TAB 100MG 06/13/ CLOZAPINE TAB 25MG 06/13/ CLOZAPINE TAB 50MG 06/02/ ZYPREXA TAB 10MG 06/02/ GEODON CAP 40MG 06/02/ GEODON CAP 80MG 06/02/ ZYPREXA TAB 5MG 05/29/ ZYPREXA TAB 2.5MG 05/29/ ZYPREXA TAB 5MG 05/29/ ZYPREXA TAB 10MG 05/10/ GEODON CAP 80MG 05/10/ GEODON CAP 20MG 05/01/ GEODON CAP 40MG 05/01/ GEODON CAP 60MG RT
33 DOS RX_Num/ Quantity Days Supply Product/Procedure Description Proc Code Z 12/29/ /22/ /22/ ABILIFY TAB 5MG 12/15/ /08/ /01/ /26/ ABILIFY TAB 5MG 11/24/ /15/ /10/ CLOZAPINE TAB 25MG 11/10/ CLOZAPINE TAB 100MG 10/27/ ABILIFY TAB 5MG 10/27/ CLOZAPINE TAB 200MG 10/27/ CLOZAPINE TAB 50MG 10/01/ CLOZAPINE TAB 200MG 10/01/ CLOZAPINE TAB 50MG 10/01/ ABILIFY TAB 5MG 09/01/ ABILIFY TAB 5MG 09/01/ CLOZAPINE TAB 200MG 09/01/ CLOZAPINE TAB 50MG 08/26/ ABILIFY TAB 2MG 08/26/ ABILIFY TAB 5MG 08/01/ CLOZAPINE TAB 50MG 08/01/ CLOZAPINE TAB 200MG 07/08/ CLOZAPINE TAB 25MG 07/08/ CLOZAPINE TAB 50MG 07/01/ CLOZAPINE TAB 200MG 07/01/ CLOZAPINE TAB 50MG 07/01/ CLOZAPINE TAB 100MG 06/25/ CLOZAPINE TAB 200MG 06/11/ RISPERDAL TAB 0.5MG 06/11/ CLOZAPINE TAB 100MG 06/01/ CLOZAPINE TAB 25MG 06/01/ CLOZAPINE TAB 50MG 06/01/ RISPERDAL TAB 1MG 05/20/ RISPERDAL TAB 1MG 05/20/ CLOZAPINE TAB 25MG 05/20/ CLOZAPINE TAB 50MG 05/06/ RISPERDAL TAB 2MG 05/06/ RISPERDAL TAB 3MG RT
34 DOS RX_Num/ Quantity Days Supply Product/Procedure Description Proc Code Z 11/13/ CLOZAPINE TAB 100MG 10/15/ CLOZAPINE TAB 25MG 10/14/ CLOZAPINE TAB 100MG 09/23/ CLOZAPINE TAB 200MG 09/23/ CLOZAPINE TAB 25MG 09/23/ CLOZAPINE TAB 100MG 09/01/ CLOZAPINE TAB 200MG 09/01/ CLOZAPINE TAB 25MG 08/12/ SEROQUEL TAB 100MG 08/12/ CLOZAPINE TAB 50MG 08/12/ CLOZAPINE TAB 200MG 08/08/ CLOZAPINE TAB 50MG 08/08/ CLOZAPINE TAB 100MG 08/08/ SEROQUEL TAB 100MG 08/01/ CLOZAPINE TAB 50MG 08/01/ CLOZAPINE TAB 100MG 08/01/ SEROQUEL TAB 100MG 08/01/ CLOZAPINE TAB 25MG 07/18/ CLOZAPINE TAB 50MG 07/18/ SEROQUEL TAB 100MG 07/03/ CLOZAPINE TAB 100MG 07/03/ CLOZAPINE TAB 25MG 07/03/ SEROQUEL TAB 200MG 06/24/ SEROQUEL TAB 300MG 06/01/ SEROQUEL TAB 200MG 06/01/ SEROQUEL TAB 100MG 05/12/ SEROQUEL TAB 200MG 05/01/ SEROQUEL TAB 100MG RT
35 DOS RX_Num/ Quantity Days Supply Product/Procedure Description Proc Code Z 12/01/ ABILIFY TAB 15MG 12/01/ CLOZAPINE TAB 50MG 12/01/ CLOZAPINE TAB 200MG 11/03/ ABILIFY TAB 10MG 11/03/ CLOZAPINE TAB 50MG 11/03/ CLOZAPINE TAB 200MG 10/08/ ABILIFY TAB 10MG 10/01/ CLOZAPINE TAB 100MG 10/01/ ABILIFY TAB 5MG 10/01/ CLOZAPINE TAB 50MG 09/29/ CLOZAPINE TAB 100MG 09/22/ CLOZAPINE TAB 100MG 09/09/ CLOZAPINE TAB 100MG 09/01/ CLOZAPINE TAB 50MG 09/01/ ABILIFY TAB 5MG 09/01/ CLOZAPINE TAB 200MG 08/27/ ABILIFY TAB 5MG 08/26/ CLOZAPINE TAB 50MG 08/01/ CLOZAPINE TAB 50MG 08/01/ CLOZAPINE TAB 200MG 07/16/ CLOZAPINE TAB 200MG 07/16/ CLOZAPINE TAB 25MG 07/16/ CLOZAPINE TAB 50MG 07/03/ CLOZAPINE TAB 25MG 07/01/ CLOZAPINE TAB 25MG 07/01/ CLOZAPINE TAB 200MG 06/26/ CLOZAPINE TAB 25MG 06/01/ CLOZAPINE TAB 200MG 06/01/ CLOZAPINE TAB 25MG 05/24/ CLOZAPINE TAB 200MG 05/12/ ABILIFY TAB 10MG 05/12/ CLOZAPINE TAB 50MG 05/07/ CLOZAPINE TAB 25MG 05/07/ CLOZAPINE TAB 100MG 05/07/ ABILIFY TAB 15MG RT
36 DOS RX_Num/ Quantity Days Supply Product/Procedure Description Proc Code Z 12/29/ CLOZAPINE TAB 100MG 12/29/ /26/ RISPERDAL INJ 25MG 12/22/ CLOZAPINE TAB 100MG 12/22/ /15/ /15/ CLOZAPINE TAB 100MG 12/10/ RISPERDAL INJ 25MG 12/08/ CLOZAPINE TAB 100MG 12/08/ /02/ CLOZAPINE TAB 100MG 12/01/ /25/ CLOZAPINE TAB 100MG 11/24/ /18/ RISPERDAL INJ 25MG 11/18/ CLOZAPINE TAB 100MG 11/17/ /13/ RISPERDAL INJ 50MG 11/10/ CLOZAPINE TAB 100MG 11/10/ /04/ CLOZAPINE TAB 100MG 11/03/ /29/ RISPERDAL INJ 50MG 10/27/ CLOZAPINE TAB 100MG 10/27/ /20/ /20/ CLOZAPINE TAB 100MG 10/16/ RISPERDAL INJ 50MG 10/13/ CLOZAPINE TAB 100MG 10/13/ /08/ /07/ CLOZAPINE TAB 100MG 10/02/ FAZACLO TAB 100MG 10/01/ /30/ RISPERDAL INJ 50MG 09/25/ FAZACLO TAB 100MG 09/24/ /18/ FAZACLO TAB 100MG 09/17/ /15/ RISPERDAL INJ 50MG 09/11/ FAZACLO TAB 100MG 09/10/ /04/ FAZACLO TAB 100MG 09/04/ RISPERDAL INJ 50MG 09/03/ /28/ FAZACLO TAB 100MG 08/27/ INVEGA TAB 3MG 08/27/ /25/ RISPERDAL INJ 50MG 08/20/ /19/ FAZACLO TAB 100MG 08/13/ FAZACLO TAB 100MG 08/13/ /07/ FAZACLO TAB 100MG 08/06/ /05/ INVEGA TAB 3MG 08/05/ RISPERDAL INJ 50MG 07/30/ /24/ FAZACLO TAB 100MG 07/24/ INVEGA TAB 3MG 07/23/ RISPERDAL INJ 50MG RT
37 DOS RX_Num/ Quantity Days Supply Product/Procedure Description Proc Code 07/23/ /21/ FAZACLO TAB 100MG 07/21/ INVEGA TAB 3MG 07/18/ FAZACLO TAB 100MG 07/18/ INVEGA TAB 3MG 07/16/ /11/ INVEGA TAB 3MG 07/11/ FAZACLO TAB 100MG 07/09/ /03/ FAZACLO TAB 100MG 07/03/ INVEGA TAB 3MG 07/03/ RISPERDAL TAB 1MG 07/02/ /30/ RISPERDAL TAB 1MG 06/27/ FAZACLO TAB 100MG 06/25/ FAZACLO TAB 100MG 06/25/ RISPERDAL INJ 50MG 06/25/ /25/ LEUKOCYTE (WBC) AUTOMATE 06/23/ FAZACLO TAB 25MG 06/23/ FAZACLO TAB 100MG 06/19/ INVEGA TAB 3MG 06/18/ /17/ FAZACLO TAB 25MG 06/16/ FAZACLO TAB 25MG 06/16/ FAZACLO TAB 100MG 06/15/ FAZACLO TAB 100MG 06/15/ RISPERDAL TAB 1MG 06/11/ /11/ RISPERDAL INJ 50MG 06/04/ /29/ FAZACLO TAB 25MG 05/28/ RISPERDAL INJ 50MG 05/28/ /27/ FAZACLO TAB 25MG 05/23/ FAZACLO TAB 25MG 05/22/ FAZACLO TAB 100MG 05/22/ INVEGA TAB 3MG 05/22/ RISPERDAL TAB 2MG 05/21/ /14/ RISPERDAL INJ 50MG 05/14/ /08/ FAZACLO TAB 25MG 05/08/ FAZACLO TAB 100MG 05/07/ RT
Iowa Medicaid Mental Health Advisory Group Meeting February 13, Tentative Agenda
CHESTER J. CULVER, GOVERNOR PATTY JUDGE, LT. GOVERNOR DEPARTMENT OF HUMAN SERVICES EUGENE I. GESSOW, DIRECTOR Iowa Medicaid Mental Health Advisory Group Meeting February 13, 2009 Location: Iowa Medicaid
More informationIOWA MEDICAID DRUG UTILIZATION REVIEW COMMISSION 100 Army Post Road (515)
IOWA MEDICAID DRUG UTILIZATION REVIEW COMMISSION 100 Army Post Road (515) 974-3131 -866-626-0216 Brett Faine, Pharm.D. Larry Ambroson, R.Ph. Casey Clor, M.D. Professional Staff: Mark Graber, M.D., FACEP
More informationU T I L I Z A T I O N E D I T S
I N D I A N A H E A L T H C O V E R A G E P R O G R A M S U T I L I Z A T I O N E D I T S A P R I L 1 9, 2 0 1 2 s for s Refer to Provider Bulletin BT200709 for additional information regarding the Mental
More informationPharmacy Benefit Management (PBM) Program FORMULARY/PRODUCT RESTRICTIONS
Workforce Safety & Insurance Revised Document Date: 07/21/2015 1600 E Century Ave Ste 1 PO Box 5585 Bismarck, ND 58506-5585 701.328.3800 1.800.777.5033 www.workforcesafety.com Pharmacy Benefit Management
More informationBeneficiary Advisory Panel Handout Uniform Formulary Decisions 23 June 2011
Beneficiary Advisory Panel Handout Uniform Formulary Decisions 23 June 211 PURPOSE: The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinical effectiveness
More informationSouth Carolina Department of Health and Human Services Post Office Box 8206 Columbia, South Carolina
South Carolina Department of Health and Human Services Post Office Box 8206 Columbia, South Carolina 29202-8206 Pharmacy and Therapeutics (P&T) Committee Meeting MINUTES 1. Call to Order A meeting of the
More informationIdaho DUR Board Meeting Minutes
Idaho DUR Board Meeting Minutes Date: January 21, 2016 Time: 9am-1:30pm Location: Idaho Medicaid, 3232 Elder Street, Boise, Idaho, Conference Room D-West Moderator: Mark Turner, M.D. Committee Members
More informationIowa Medicaid Drug Utilization Review Commission Meeting Minutes May 5, 2010
Iowa Medicaid Drug Utilization Review Commission Meeting Minutes May 5, 2010 Attendees: Commission Members Craig Logemann, R.Ph., Pharm.D., BCPS; Sara Schutte-Schenck, D.O., FAAP; Laurie Pestel, Pharm.D.;
More informationNew Hampshire Healthy Families CLINICAL POLICY
New Hampshire Healthy Families CLINICAL POLICY DEPARTMENT: Pharmacy DOCUMENT NAME: Opioid Analgesics PAGE: 1 o f 6 REFERENCE NUMBER: NH.PPA.13 EFFECTIVE DATE: 6/1/2016 REPLACES DOCUMENT: N/A RETIRED: REVIEWED:
More informationPharmacy Medical Necessity Guidelines: Atypical Antipsychotic Medications. Effective: December 12, 2017
Pharmacy Medical Necessity Guidelines: Effective: December 12, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED)
More informationA Brief Overview of Psychiatric Pharmacotherapy. Joel V. Oberstar, M.D. Chief Executive Officer
A Brief Overview of Psychiatric Pharmacotherapy Joel V. Oberstar, M.D. Chief Executive Officer Disclosures Some medications discussed are not approved by the FDA for use in the population discussed/described.
More informationAntipsychotic Medications Age and Step Therapy
Market DC *- Florida Healthy Kids Antipsychotic Medications Age and Step Therapy Override(s) Approval Duration Prior Authorization 1 year Quantity Limit *Virginia Medicaid See State Specific Mandates *Indiana
More informationPharmacy Medical Necessity Guidelines: Atypical Antipsychotic Medications. Effective: February 20, 2017
Pharmacy Medical Necessity Guidelines: Effective: February 20, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED)
More informationPharmacy Medical Necessity Guidelines: Antipsychotic Medications
Pharmacy Medical Necessity Guidelines: Antipsychotic Medications Effective: July. 1, 2016 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy
More informationMedicaid Perspective
Prescription Opioid Fraud and Abuse: Medicaid Perspective Presenter: Gary P. Gilmore, B.S., R.Ph. Director, Analysis & Reporting Office of Clinical Affairs Deputy Director, Pharmacy Program Objectives:
More informationDrugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical criteria
Drug/Drug Class Antipsychotics Clinical Criteria Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical criteria Prior
More informationJudges Reference Table for the March 2016 Psychotropic Medication Utilization Parameters for Foster Children
Judges Reference Table for the Psychotropic Medication Utilization Parameters for Foster Children Stimulants for treatment of ADHD Preschool (Ages 3-5 years) Child (Ages 6-12 years) Adolescent (Ages 13-17
More informationAntipsychotics Prior Authorization Criteria for Louisiana Fee for Service and MCO Medicaid Recipients
Antipsychotics Prior Authorization Criteria for Louisiana Fee for Service and MCO Medicaid Recipients Preferred Agents (Oral) a Amitriptyline/Perphenazine (Generic) Aripiprazole Tablet (Generic) b Chlorpromazine
More informationI. Mechanisms of action the role of prostaglandins a. Mediators of inflammation b. and much more
NSAID steroid update Leo Semes, OD, FAAO I. Mechanisms of action the role of prostaglandins a. Mediators of inflammation b. and much more II. Topical NSAIDS ophthalmic application III. Oral NSAIDs a. Precautions
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Invega) Reference Number: CP. PMA.10.11.19 Effective Date: 10.06.16 Last Review Date: 04.18 Line of Business: CenpaticoMedicaid Revision Log See Important Reminder at the end of this
More informationPequot Health Care Opioid Analgesic Quantity Program*
Pequot Health Care 1 Annie George Drive Mashantucket, CT 06338 Phone: 1-888-779-6638 Fax: 1-860-396-6494 Pequot Health Care Opioid Analgesic Quantity Program* Effective January 2018 *Quantity Program limits
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Vraylar) Reference Number: CP.PMN.91 Effective Date: 11.16.16 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationPharmacy Medical Necessity Guidelines: Antipsychotic Medications
Pharmacy Medical Necessity Guidelines: Effective: October 1, 2016 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit
More informationALAMEDA COUNTY BEHAVIORAL HEALTH CARE SERVICES MEDICATION FORMULARY
ANTIDEPRESSANTS Serotonin Selective Reuptake Inhibitors citalopram 10, 20, 40 mg, 10 mg/5cc $ 0.40 No escitalopram 10, 20 mg $ 2.60 Yes fluoxetine 10, 20 mg, 20 mg/5 ml $ 0.40 Yes fluvoxamine 25, 50, 100
More informationCLINICAL POLICY Clinical Policy: Extended Release Opioid Analgesics
Reference Number: AZ.CP.PMN.97 Effective Date: 02.11 Last Review Date: 02.18 Line of Business: Medicaid- AHCCCS Revision Log See Important Reminder at the end of this policy for important regulatory and
More informationClinical Policy: Clozapine orally disintegrating tablet (Fazaclo) Reference Number: CP.PMN.12 Effective Date: Last Review Date: 02.
Clinical Policy: Clozapine orally disintegrating tablet (Fazaclo) Reference Number: CP.PMN.12 Effective Date: 08.01.15 Last Review Date: 02.18 Line of Business: Medicaid Revision Log See Important Reminder
More informationDrug Use Evaluation: Short Acting Opioids (SAO)
Drug Use Evaluation: Short Acting Opioids (SAO) Summary Short acting opioid analgesics are one of the most prescribed (top 10) and highest cost (top 20) medication classes for the Oregon Fee For Service
More informationSection 2 Class III, IV & V Pharmaceuticals Page 13
Section 2 Class III, IV & V Pharmaceuticals Page 13 ACETAMINOPHEN W/ CODEINE #3 30MG TABS (GENERIC TYLENOL) #100 41.99 ACETAMINOPHEN W/ CODEINE #3 30MG TABS #1000 298.99 ACETAMINOPHEN W/ CODEINE #4 60MG
More informationIMPORTANT NOTICE. Changes to dispensing of some Behavioral Health Medications for DC Healthcare Alliance members
IMPORTANT NOTICE Changes to dispensing of some Behavioral Health Medications for DC Healthcare Alliance members These changes apply only to members covered under the DC Healthcare Alliance program Alliance
More informationIdaho DUR Board Meeting Minutes
Date: July 16, 2015 Time: 9am-1:30pm Idaho DUR Board Meeting Minutes Location: Idaho Medicaid, 3232 Elder Street, Boise, Idaho, Conference Room D-West Moderator: Mark Turner, M.D. Committee Member Present:
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Rexulti) Reference Number: CP.PMN.68 Effective Date: 11.05.15 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Revision Log See Important Reminder
More informationNew Product to Market: Lonhala Magnair
Drug Review and The following tables list the Agenda items as well as the that are scheduled to be presented and reviewed at the May 17, 2018 meeting of the Pharmacy and Therapeutics Advisory Committee.
More informationIowa Medicaid Drug Utilization Review Commission Meeting Minutes March 3, 2010
Iowa Medicaid Drug Utilization Review Commission Meeting Minutes March 3, 2010 Attendees: Commission Members Bruce Alexander, R.Ph., Pharm.D., BCPP; Craig Logemann, R.Ph., Pharm.D., BCPS; Sara Schutte-Schenck,
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Antipsychotics
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Antipsychotics A. Prescriptions That Require Prior Authorization Prescriptions for Antipsychotics
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Saphris) Reference Number: CP.PMN.15 Effective Date: 12.01.14 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Revision Log See Important Reminder
More informationKentucky Department for Medicaid Services Pharmacy and Therapeutics Advisory Committee Recommendations
Kentucky Department for Medicaid Services Pharmacy and May 17, 2018 The following chart provides a summary of the recommendations that were made by the Pharmacy and Therapeutics (P&T) Advisory Committee
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Invega Sustenna, Invega Trinza) Reference Number: CP.PHAR.291 Effective Date: 12.01.16 Last Review Date: 08.18 Line of Business: Medicaid See Important Reminder at the end of this policy
More informationAETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization
AETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization Policy applies to all formulary and non-formulary schedules II V opioid narcotics, including tramadol and codeine, as
More informationIowa Medicaid Drug Utilization Review (DUR) Commission Meeting November 5, 2008
CHESTER J. CULVER, GOVERNOR PATTY JUDGE, LT. GOVERNOR DEPARTMENT OF HUMAN SERVICES EUGENE I. GESSOW, DIRECTOR Iowa Medicaid Drug Utilization Review (DUR) Commission Meeting November 5, 2008 Location: Iowa
More informationThese reports were prepared pursuant to directive contained in Section 10 of Senate File 2425 which is listed below:
CHESTER J. CULVER, GOVERNOR PATTY JUDGE, LT. GOVERNOR DEPARTMENT OF HUMAN SERVICES EUGENE I. GESSOW, DIRECTOR January 15, 2009 Michael Marshall Secretary of Senate State Capitol LOCAL Mark Brandsgard Chief
More informationClinical Policy: Olanzapine Long-Acting Injection (Zyprexa Relprevv) Reference Number: CP.PHAR.292 Effective Date: Last Review Date: 08.
Clinical Policy: (Zyprexa Relprevv) Reference Number: CP.PHAR.292 Effective Date: 12.01.16 Last Review Date: 08.18 Line of Business: Medicaid See Important Reminder at the end of this policy for important
More informationHOSPITAL BASED INPATIENT PSYCHIATRIC SERVICES (HBIPS) MEASURE SET
HOSPITAL BASED INPATIENT PSYCHIATRIC SERVICES (HBIPS) MEASURE SET Kathy Wonderly RN, MSEd, CPHQ Consultant Developed: February, 2013 Most recently revised: December 2018 The Psychiatric Measure Set CMS
More informationGeneric Label Name Drug Strength Dosage Form Example Product (s) MME/Unit ACETAMINOPHEN WITH CODEINE
STATE OF TENNESSEE DEPARTMENT OF FINANCE AND ADMINISTRATION DIVISION OF HEALTH CARE FINANCE AND ADMINISTRATION BUREAU OF TENNCARE 3 Great Circle Road NASHVILLE, TENNESSEE 37243 This notice is to advise
More informationClinical Policy: Olanzapine Orally Disintegrating Tablet (Zyprexa Zydis) Reference Number: CP.PMN.29 Effective Date: Last Review Date: 02.
Clinical Policy: (Zyprexa Zydis) Reference Number: CP.PMN.29 Effective Date: 08.01.15 Last Review Date: 02.19 Line of Business: Medicaid See Important Reminder at the end of this policy for important regulatory
More informationCurbing Prescription Drug Abuse in Medicaid
Curbing Prescription Drug Abuse in Medicaid Joint Legislative Health Care Oversight Committee October 12, 2010 Dr. Lisa Weeks, BSPharm, PharmD Pharmacy and Ancillary Services Division of Medical Assistance
More informationAttention: Behavioral Health Providers, Pharmacists and Prescribers N.C. Medicaid and N.C. Health Choice Preferred Drug List Changes - UPDATE
Attention: Behavioral Health Providers, Pharmacists and Prescribers N.C. Medicaid and N.C. Health Choice Drug List Changes - UPDATE Note: This article was previously published in the December 2014 Medicaid
More informationCommissioner for the Department for Medicaid Services Selections for Preferred Products
Commissioner for the Department for Medicaid Services Selections for Preferred Products This is a summary of the final Preferred Drug List (PDL) selections made by the Commissioner for the Department for
More informationNorthSTAR. Pharmacy Manual
NorthSTAR Pharmacy Manual Revised October, 2008 Table of I. Introduction II. III. IV. Antidepressants New Generation Antipsychotic Medications Mood Stabilizers V. ADHD Medications VI. Anxiolytics and Sedative-Hypnotics
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Effective Date: 04.18 Last Review Date: 04.18 Line of Business: Medicaid- AHCCCS Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description
More informationAvoid paying too much for your prescriptions
Quality health plans & benefits Healthier living Financial well-being Intelligent solutions 2017 Aetna Rx Step Program Medicine List Avoid paying too much for your prescriptions It s important to try to
More informationA Statewide Evaluation of Opioid Prescribing Patterns with an Emphasis on Drug Diversion and Substance Abuse
A Statewide Evaluation of Opioid Prescribing Patterns with an Emphasis on Drug Diversion and Substance Abuse INVESTIGATIVE TEAM: STEERING COMMITTEE FOR THE TUFTS HEALTH CARE INSTITUTE ON OPIOID RISK MANAGEMENT
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: AZ.CP.PHAR.10.11.10 Effective Date: 07.16 Last Review Date: 09.12.18 Line of Business: Medicaid Arizona Revision Log See Important Reminder at the end of this policy
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.CPA.259 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Abilify Maintena, Aristada, Aristada Initio) Reference Number: CP.PHAR.290 Effective Date: 12.01.16 Last Review Date: 08.18 Line of Business: Medicaid Coding Implications Revision Log
More informationPrior Authorization for Opioid Products Indicated for Pain Management
Kansas Medical Assistance Program PA Phone 800-933-6593 PA Fax 800-913-2229 Amerigroup PA Pharmacy Phone 855-201-7170 PA Pharmacy Fax 800-601-4829 Sunflower PA Pharmacy Phone 877-397-9526 PA Pharmacy Fax
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Opioid Analgesics Reference Number: HIM.PA.139 Effective Date: 12.01.17 Last Review Date: 11.17 Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: HIM.PA.139 Effective Date: 12.01.17 Last Review Date: 02.18 Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the end of this policy
More informationFollow-up to Previous Reviews. Foster Children Prescribers (Nurse Practitioner Practice Sites)
15 January 2015 1 Follow-up to Previous Reviews Foster Children Prescribers (Nurse Practitioner Practice Sites) 2 Foster Children Prescribers (Nurse Practitioner Practice Sites) 3 Ongoing Reviews Buprenorphine
More informationIt is the policy of health plans affiliated with Centene Corporation that Seroquel XR is medically necessary when the following criteria are met:
Clinical Policy: (Seroquel XR) Reference Number: CP.PMN.64 Effective Date: 12.01.14 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Revision Log See Important
More informationIdaho DUR Board Meeting Minutes
Idaho DUR Board Meeting Minutes Date: Jan. 16, 2014 Time: 9am-1pm Location: Idaho Medicaid, 3232 Elder Street, Boise, Idaho, Conference Room D-West Moderator: Mark Turner, M.D. Committee Member Present:
More informationIdaho DUR Board Meeting Minutes
Idaho DUR Board Meeting Minutes Date: July 20, 2017 Time: 9am-12:30pm Location: Holiday Inn Boise Airport 2970 West Elder Street, Boise, Idaho, 83705 Moderator: David Agler, M.D. Committee Member Present:
More informationNeighborhood Medicaid Formulary Changes: June 2017
Neighborhood Medicaid Formulary Changes: June 2017 The following changes to the Neighborhood Medicaid Formulary were recently approved by the Pharmacy and Therapeutics (P&T) Committee. All changes were
More informationStep Therapy Criteria
Tier 5 Formulary Step Therapy 2016 Updated: 05/24/2016 Effective: 06/01/2016 What is Step Therapy? Some prescription drugs require step therapy (ST). In some cases, the plan requires you to first try certain
More informationSouth Carolina Department of Health and Human Services Post Office Box 8206 Columbia, South Carolina
South Carolina Department of Health and Human Services Post Office Box 8206 Columbia, South Carolina 29202-8206 Pharmacy and Therapeutics (P&T) Committee Meeting MINUTES 1. Call to Order A meeting of the
More informationTexas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationABILIFY INJ. Products Affected Step 2: ABILIFY MAINTENA PREFILLED SYRINGE 300 MG INTRAMUSCULAR ABILIFY MAINTENA PREFILLED SYRINGE 400 MG INTRAMUSCULAR
ABILIFY INJ ABILIFY MAINTENA PREFILLED SYRINGE 300 MG ABILIFY MAINTENA PREFILLED SYRINGE 400 MG ABILIFY MAINTENA SUSPENSION RECONSTITUTED ER 300 MG Claim will pay automatically for ABILIFY MAINTENA if
More informationClinical Policy: Opioid Analgesics Reference Number: OH.PHAR.PPA.13 Effective Date: 10/2017 Last Review Date: 6/2018 Line of Business: Medicaid
Clinical Policy: Reference Number: OH.PHAR.PPA.13 Effective Date: 10/2017 Last Review Date: 6/2018 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationAcetaminophen/Aspirin/Ibuprofen Containing Immediate Release Opioid Analgesics: Quantity Limit Policy
DRUG POLICY Acetaminophen/Aspirin/Ibuprofen Containing Immediate Release Opioid Analgesics: Quantity Limit Policy BENEFIT APPLICATION Benefit determinations are based on the applicable contract language
More informationCONTRAINDICATIONS TABLE
CONTRAINDICATIONS TABLE Generic Name Brand Name Contraindications Amphetamine Salts Adderall, Adderall XR Hypersensitivity to amphetamine, dextroamphetamine, or other sympathomimetic amines Advanced arteriosclerosis
More informationNews & Views. Antipsychotics on Maryland Medicaid PDL and Coverage of a 30-day Emergency Supply of Atypical Antipsychotics
Maryland Medicaid Pharmacy Program News & Views February 2011 Maryland Department of Health and Mental Hygiene /Office of Systems, Operations and Pharmacy Antipsychotics on Maryland Medicaid PDL and Coverage
More informationPROPOSED DUR CRITERIA FOR MANAGING OPIOID USE AND MINIMIZING RISK OF OVERDOSE
BACKGROUND PROPOSED DUR CRITERIA FOR MANAGING OPIOID USE AND MINIMIZING RISK OF OVERDOSE In March, 2016, the CDC released the final version of their Guidelines for Prescribing Opioids for Chronic Pain.
More informationClinical Policy: Toremifene (Fareston) Reference Number: CP.PMN.126 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Fareston) Reference Number: CP.PMN.126 Effective Date: 04.01.10 Last Review Date: 05.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationIOWA MEDICAID DRUG UTILIZATION REVIEW COMMISSION 100 Army Post Road 5)
IOWA MEDICAID DRUG UTILIZATION REVIEW COMMISSION 100 Army Post Road 5) 974-3131 -866-626-0216 Brett Faine, Pharm.D. Larry Ambroson, R.Ph. Brian Couse, M.D. Date: February 10, 2015 Mark Graber, M.D., FACEP,
More informationIdaho DUR Board Meeting Minutes. Committee Member Present: Matthew Hyde, Pharm.D., Perry Brown M.D., Paul Cady, Pharm.D., Ryan Heyborne M.D.
Date: February 16, 2017 Time: 9am-12:15pm Idaho DUR Board Meeting Minutes Location: Idaho Medicaid, 3232 Elder Street, Boise, Idaho, Conference Room D-West Moderator: Perry Brown, M.D. Committee Member
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: LA.PPA.12 Effective Date: 02/11 Last Review Date: 01/18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of this policy for
More informationAppendix D: Drug Tables
Appendix D: Drug Tables A. Short-acting, Orally Administered Opioids Table D-1: Use of Short-acting, Orally Administered Opioids in Adults [198] Additional Maximum APAP dose: 4000 mg/d (2000 mg/d in chronic
More informationCriteria for Child Psychiatrist on the Use of Selected Psychotropic Medications in Children & Adolescents
Criteria for Child Psychiatrist on the Use of Selected Psychotropic Medications in Children & Adolescents DRUG NAME INDICATIONS / ACCEPTABLE USES PRIOR STIMULANT/ADHD DRUGS Daytrana (methylphenidate) ADHD
More informationOptima Health Community Care (OHCC) Maximum Allowable Daily Dosage and Quantity Limits April - June 2018
With the safety of our members in mind, we regularly review recommendations from the Food and Drug Administration (FDA) and evidence-based treatment guidelines from the medical literature with our Pharmacy
More informationIdaho DUR Board Meeting Minutes
Idaho DUR Board Meeting Minutes Date: October 16, 2014 Time: 9am-2pm Location: Idaho Medicaid, 3232 Elder Street, Boise, Idaho, Conference Room D-West Moderator: Mark Turner, M.D. Committee Member Present:
More informationNews & Views. Maryland Medicaid Mental Health Formulary Revisions. Responsible use of Intervention and Outcome Codes
Maryland Medicaid Pharmacy Program News & Views June 2009 Maryland Department of Health and Mental Hygiene / Office of Systems, Operations and Pharmacy Maryland Medicaid Mental Health Formulary Revisions
More informationANTICONVULSANTS. Details. Step Therapy Criteria Date Effective: April 1, 2019
Step Therapy Date Effective: April 1, 2019 ANTICONVULSANTS APTIOM TABLET 200 MG ORAL APTIOM TABLET 400 MG ORAL APTIOM TABLET 600 MG ORAL APTIOM TABLET 800 MG ORAL BANZEL SUSPENSION 40 MG/ML ORAL BANZEL
More informationRelative Cost/Month. Less than $10. Loratadine Liquid* $10-$15 Cetirizine liquid 1mg/mL*
Allergy Chlorpheniramine Tablet* Diphenhydramine Tablet* Diphenhydramine Liquid* Loratadine Tablet* Cetirizine Tablet* Loratadine 10mg ODT* Less than $10 Loratadine Liquid* $10-$15 Cetirizine liquid 1mg/mL*
More informationOpioid Management Program May 2018
Opioid Management Program May 2018 What Is the Opioid Management Program? This program is based on guidelines developed by the U.S. Centers for Disease Control and Prevention (CDC). It consists of daily
More information: Opioid Quantity Limits
March 7, 2017 2017-09: Opioid Quantity Limits The Louisiana Department of Health (LDH), in conjunction with the Louisiana Medicaid Drug Utilization Review (DUR) Board, has revised quantity limits for selected
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: potassium (Zipsor), (Zorvolex) Reference Number: CP.CPA.280 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end
More informationIowa Medicaid Drug Utilization Review Commission Meeting Minutes October 5, 2011
Iowa Medicaid Drug Utilization Review Commission Meeting Minutes October 5, 2011 Attendees: Commission Members Mark Graber, M.D., FACEP; Casey Clor, M.D. ; Craig Logemann, R.Ph., Pharm.D., BCPS; Sara Schutte-Schenck,
More informationSHIP TRAMADOL TO UNITED STATES
SHIP TRAMADOL TO UNITED STATES Ship Tramadol To United States What is the pill tramadol 50mg Dogs tramadol and benadryl Can u take tramadol with paracetamol and ibuprofen 4 50 mg tramadol Tramadol detox
More informationReview of Psychotrophic Medications. (An approved North Carolina Division of Health Services Regulation Continuing Education Course)
Review of Psychotrophic Medications (An approved North Carolina Division of Health Services Regulation Continuing Education Course) Common Psychiatric Disorders *Schizophrenia *Depression *Bipolar Disorder
More informationPL CE LIVE February 2011 Forum
February 2011 PL CE LIVE Kristin W. Weitzel, Pharm.D., CDE, FAPhA Associate Editor and Director of Editorial Projects Pharmacist s Letter/Prescriber s Letter Atypical Antipsychotics Atypical Antipsychotics
More informationPharmacy Medical Necessity Guidelines: Antipsychotic Medications
Pharmacy Medical Necessity Guidelines: Effective: April 1, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit
More informationPresented by Sata Hackenbruck 6 August 2009 State of Oregon SAS Users Group Meeting
Presented by Sata Hackenbruck 6 August 2009 State of Oregon SAS Users Group Meeting Explore following SAS text functions: COMPRESS TRANWRD SCAN Here is the problem I am analyzing pharmacy data and I want
More informationPharmacy Medical Necessity Guidelines: Opioid Analgesics
Pharmacy Medical Necessity Guidelines: Effective: January 1, 2019 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit
More informationCyclosporine is an immunosuppressant
Indiana Drug Utilization Review Board September, 1998 Issue No. 4 Generic Differences Associated with Cyclosporine Products Cyclosporine is an immunosuppressant agent used in the prophylaxis of organ rejection
More informationNebraska Medicaid Criteria. Abilify Maintena
Nebraska Medicaid Criteria All initial and renewal authorizations are for 12 months in duration. Abilify Maintena *Criteria for Authorization for Abilify Maintena The individual has a current DSM diagnosis
More informationDrug Utilization Review Board
Drug Utilization Review Board Oklahoma Health Care Authority 2401 N.W. 23rd Street, Suite 1A Oklahoma City, Oklahoma 73107 Ponca Room Wednesday May 9, 2012 6:00 p.m. The University of Oklahoma Health Sciences
More information